Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 1/20 | 0.39 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29859591 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ALMNAABL1 | |
| SCHEMBL29859265 | 0.90 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ALMNAABL1 | |
| SCHEMBL19989556 | 0.90 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ALMNAABL1 | |
| SCHEMBL19989416 | 0.84 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2ALMNAABL1 | |
| SCHEMBL29859488 | 0.84 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2ALMNAABL1 | |
| SCHEMBL29498495 | 0.83 | ABL1 (0.46) | ALDH1A1MEN1KMT2ALMNAABL1 | |
| SCHEMBL19994863 | 0.83 | ABL1 (0.46) | ALDH1A1MEN1KMT2ALMNAABL1 | |
| SCHEMBL16014614 | 0.80 | ALDH1A1 (0.47) | ALDH1A1LMNATSHR | |
| SCHEMBL16492268 | 0.78 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2ALMNAABL1 | |
| SCHEMBL17790336 | 0.78 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2ALMNAABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715608-B | Indazole compounds for use in tendon and/or ligament injuries | 诺华股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3515894-B1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2021-04-07 | — | — | EP | disclosed |
| EP-3515894-A1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | Novartis AG (CH) | 2019-07-31 | — | — | EP | disclosed |
| US-10112907-B2 | Substituted indazoles for treating tendon and/or ligament injuries | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180086716-A1 | Indazole Compounds for Use in Tendon and/or Ligament Injuries | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2018-03-29 | — | — | US | disclosed |
| WO-2018055550-A1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112907-B2 | Substituted indazoles for treating tendon and/or ligament injuries | SLC10A2, MMP1, TNNI3 | ALDH1A1 442/4885MEN1 2014/4885KMT2A 3008/4885 |
| US-20180086716-A1 | Indazole Compounds for Use in Tendon and/or Ligament Injuries | MMP1, SLC10A2, TNNI3 | ALDH1A1 414/4885MEN1 2007/4885KMT2A 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.